In tumours treated with bevazicumab (BEV, antibody targeting VEGFA) or dibenzazepine (DBZ, inhibits NOTCH1 signalling by inhibiting γ-secretase), FABP4 staining in the vessels of DLL4-overexpressing tumours was still stronger and more extensive than in the vessels of EV tumours (P<0.01 in BEV-treated, P<0.05 in DBZ-treated tumours). Here, DLL4 is linked to neoplasm.